Illumina countersues IBS and Qiagen

(Reuters) – Genetic sequencing company Illumina Inc countersued Intelligent Bio-Systems Inc and Qiagen NV alleging infringement on three of its patents expiring in December 2022. Illumina alleged infringement on patents that are applicable to the “sequencing by synthesis technology” being used in the IBS Max-Seq and MINI-20 DNA Sequencers. The company said the suit was in response to the lawsuit brought against Illumina in March by Columbia University and IBS alleging infringement of five patents related to DNA sequencing. Qiagen acquired IBS in June. …

Bayer says Nexavar-Tarceva trial unsuccessful

(Reuters) – The combination of cancer tablets Tarceva and Nexavar to treat patients with liver cancer failed to improve overall survival rates compared with standard Nexavar treatment in a late-stage Phase III trial, drug companies involved said on Monday. Analysts at brokerage Cheuvreux said the news was a small negative for Bayer AG , the lead partner in the trial, but they left peak sales forecasts for Nexavar unchanged at 971 million euros ($1.18 billion) in 2019. …

1 33 34 35 36 37 121